Skip to main content
. Author manuscript; available in PMC: 2019 Dec 20.
Published in final edited form as: Nanoscale. 2018 Dec 20;11(1):219–236. doi: 10.1039/c8nr05784b

Figure 5. Saturated farnesol-loaded NPC formulation improved biofilm inhibition using in vitro saliva-coated hydroxyapatite disk assay.

Figure 5.

A) Scheme showing treatment regimen used with S. mutans biofilms grown in vitro on saliva-coated hydroxyapatite (sHA) disks. B) CFU/mL values obtained for biofilms formed on sHA disks for each treatment group tested. C) Biofilm dry weight values obtained for biofilms formed on sHA disks for each treatment group tested. Data shown as mean and standard deviation from n=6–10 independent assays. % p ≤ 0.001 versus PBS, & p ≤ 0.001 versus Farnesol, ∞ p ≤ 0.001 versus CCR 1, ● p ≤ 0.0001 versus CCR 4, ! p ≤ 0.0001 versus CCR 1 + Std Far, * p ≤ 0.05 versus CCR 4 + Std Far, # p ≤ 0.05 versus CCR 1 + Sat Far, and $ p ≤ 0.05 versus CCR 4 + Sat Far from One-way ANOVA with Tukey’s multiple comparisons test. Abbreviations: CFU, Colony Forming Unit; CCR, Corona-to-Core molecular weight Ratio; Far, farnesol; NPC, nanoparticle carrier.